ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 0049

IL-18 Receptor-α Signaling Pathway Contributes to Autoantibody-induced Arthritis via Neutrophil Recruitment
Abstract Number: 0050

Effect of Disease-modifying Anti-rheumatic Drugs on Lung Microenvironment of SKG Mice
Abstract Number: 0051

Identification of a Transcription Factor That Drives Polarization Toward Tissue-destructive Fibroblasts in Arthritis
Abstract Number: 0052

Elucidating Androgen Effects on Focal Erosions in TNF-Induced Inflammatory Arthritis
Abstract Number: 0053

Natural Microbial Exposure Increases Susceptibility of C57BL/6 Mice to Collagen-induced Arthritis
Abstract Number: 0054

MDSCs in Inflammatory Joints of SKG Mice Suppress T Cells and Differentiate into Osteoclasts
Abstract Number: 0055

Protective Role for Mast Cells in TNF-induced Inflammatory-Erosive Arthritis and Its Associated Lymphatic Dysfunction in Mice
Abstract Number: 0056

Pilot Study to Implement the Type 1 & 2 SLE Model in an Academic Rheumatology Clinic
Abstract Number: 0057

Accelerating AxSpA Diagnosis: Exploring At-home Self-sampling, Symptom Checkers, Medical Student-visits and Asynchronous Report-based Assessment
Abstract Number: 0058

Health System Improvement in Inpatient ANA and Serologic Test Utilization
Abstract Number: 0059

Healthcare Resource Utilization and Costs of Management of Lupus Nephritis in Adult and Juvenile Patients with Systemic Lupus Erythematosus
Abstract Number: 0060

Lower Healthcare Costs for Commercially Insured Patients with Rheumatoid Arthritis in Remission
Abstract Number: 0061

Rheumatic Diagnostic Code Trajectories for Patients with RA and SLE in a U.S. Rheumatology Registry
Abstract Number: 0062

Comparing Alzheimer’s Disease Risk in Patients with Chronic Inflammatory Autoimmune Diseases: A Medicare Cohort Study
Abstract Number: 0063

Implementability of a SLE Medication Adherence Intervention

« Previous Page
1
…
5
6
7
8
9
…
154
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].